Open a free Demat account & get ₹500 in stocks.Claim
Nifty 5025,387.40.97%H 25,501.35 · L 25,267.3as of 3:31 PM IST|Sensex82,532.191.15%H 82,897.49 · L 82,091.9as of 3:32 PM IST|Bank Nifty62,273.252.03%H 62,442.2 · L 61,488as of 3:31 PM IST|USD / INR₹93.460.48%H ₹93.92 · L ₹93.38as of 7:17 PM IST|Gold Intl (10g)₹1,16,264.980.42%H ₹1,16,874.95 · L ₹1,15,360.53upd. 8:09 PM IST|Silver Intl (1kg)₹1,43,329.271.79%H ₹1,43,990.33 · L ₹1,40,489.73upd. 8:09 PM IST|Crude WTI₹8,134.761.54%H ₹8,166.53 · L ₹7,914.19upd. 8:09 PM IST|Bitcoin₹60,73,2600.68%H ₹60,93,811.27 · L ₹60,52,708.73upd. 8:06 PM IST|Ethereum₹1,70,1421.81%H ₹1,71,681.55 · L ₹1,68,602.45upd. 8:06 PM IST|Nifty 5025,387.40.97%H 25,501.35 · L 25,267.3as of 3:31 PM IST|Sensex82,532.191.15%H 82,897.49 · L 82,091.9as of 3:32 PM IST|Bank Nifty62,273.252.03%H 62,442.2 · L 61,488as of 3:31 PM IST|USD / INR₹93.460.48%H ₹93.92 · L ₹93.38as of 7:17 PM IST|Gold Intl (10g)₹1,16,264.980.42%H ₹1,16,874.95 · L ₹1,15,360.53upd. 8:09 PM IST|Silver Intl (1kg)₹1,43,329.271.79%H ₹1,43,990.33 · L ₹1,40,489.73upd. 8:09 PM IST|Crude WTI₹8,134.761.54%H ₹8,166.53 · L ₹7,914.19upd. 8:09 PM IST|Bitcoin₹60,73,2600.68%H ₹60,93,811.27 · L ₹60,52,708.73upd. 8:06 PM IST|Ethereum₹1,70,1421.81%H ₹1,71,681.55 · L ₹1,68,602.45upd. 8:06 PM IST|
0%
real-estate

DRI Searches Cipla's Mumbai Office, Bhiwandi Depot Over Imported Drug Classification

Arth Vani DeskPublished: 1 min read
DRI Searches Cipla's Mumbai Office, Bhiwandi Depot Over Imported Drug Classification

Source: ET Real Estate

Recommended for you
Check home-loan rates & eligibility
Explore Home Loans
Listen to this article
AI voice · Podcast mode
Get IPO & market alerts free on Telegram / WhatsApp
AI Summary

The Directorate of Revenue Intelligence (DRI) recently conducted searches at pharmaceutical major Cipla's Mumbai office and Bhiwandi depot. The searches were related to the classification or exemption of an imported finished pharmaceutical product. Cipla has stated its full cooperation with authorities and anticipates no significant financial or operational impact.

Key Highlights
  • ▸The DRI searched Cipla's Mumbai office and Bhiwandi depot regarding an imported drug.
  • ▸The investigation focuses on the classification or exemption of a finished pharmaceutical product.
  • ▸Cipla is cooperating with authorities and expects no significant financial or operational impact.
Key Takeaways
  • ✓The DRI searched Cipla's Mumbai office and Bhiwandi depot regarding an imported drug.
  • ✓The investigation focuses on the classification or exemption of a finished pharmaceutical product.
  • ✓Cipla is cooperating with authorities and expects no significant financial or operational impact.

The Directorate of Revenue Intelligence (DRI) has initiated an investigation into pharmaceutical giant Cipla, conducting searches at the company's Mumbai zonal office in Vikhroli and its depot located in Bhiwandi. The focus of the DRI's inquiry is reportedly centered on the classification or exemption status of an imported finished pharmaceutical product.

The searches, carried out by the Mumbai zonal unit of the DRI, are part of a broader regulatory scrutiny aimed at ensuring compliance with customs regulations concerning the import of pharmaceutical goods. While the specific product under review has not been publicly disclosed, such investigations typically involve examining whether imported items have been correctly classified under customs tariffs or if they legitimately qualify for any claimed exemptions, which can significantly impact the duties and taxes payable.

Cipla's Response and Outlook

In response to the DRI's actions, Cipla has issued a statement confirming its full cooperation with the investigating authorities. The company emphasized its commitment to transparency and adherence to all applicable laws and regulations. Crucially, Cipla has also communicated that it does not foresee any material impact on its financial performance or day-to-day operations as a result of these ongoing proceedings. This assurance aims to allay concerns among investors and stakeholders regarding potential disruptions to the company's business.

For Indian retail investors and consumers, such regulatory actions highlight the stringent oversight within the pharmaceutical sector. The classification of imported drugs can have implications for pricing and availability, although in this specific instance, Cipla has indicated a limited impact. The pharmaceutical industry, being heavily regulated, frequently encounters such checks to maintain compliance and ensure fair trade practices.

The outcome of the DRI's investigation will depend on its findings regarding the specific imported product and Cipla's documentation. While the company remains confident, the process underscores the complexities involved in international trade and customs compliance for large corporations operating in critical sectors like pharmaceuticals.

This article is for informational purposes only and does not constitute financial or investment advice.

Recommended for you
Products related to this story — compare & act
Smart picks
Mirae Asset ELSS Tax Saver Fund
Mirae Asset Mutual Fund · ELSS
13.3%
3Y CAGR
Parag Parikh Flexi Cap Fund
PPFAS Mutual Fund · Flexi Cap
13.0%
3Y CAGR
Nippon India Small Cap Fund
Nippon India Mutual Fund · Small Cap
12.9%
3Y CAGR
Axis ELSS- Tax Saver Fund
Axis Mutual Fund · ELSS
12.0%
3Y CAGR
ICICI Prudential Balanced Advantage Fund
ICICI Prudential Mutual Fund · Hybrid
11.8%
3Y CAGR
HDFC Balanced Advantage Fund
HDFC Mutual Fund · Hybrid
11.3%
3Y CAGR

Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.

Frequently Asked Questions

Why did the DRI search Cipla's offices?

The Directorate of Revenue Intelligence (DRI) searched Cipla's Mumbai office and Bhiwandi depot to investigate the classification or exemption status of an imported finished pharmaceutical product.

What is Cipla's response to the searches?

Cipla has stated that it is fully cooperating with the authorities and does not anticipate any material impact on its financial performance or operations from these proceedings.

What does this mean for Cipla's business or investors?

While regulatory investigations can be concerning, Cipla has assured that it expects no significant financial or operational impact. For investors, this suggests the company believes the issue is manageable and will not disrupt its core business.

Stay ahead of the market

Join the Arth Vani channels

Daily news summaries, IPO & market alerts on Telegram and WhatsApp.

Related Stories

Glenmark Launches Generic Kidney Cancer Drug in US, Targeting ₹4,490 Crore Market
real-estate

Glenmark Launches Generic Kidney Cancer Drug in US, Targeting ₹4,490 Crore Market

Glenmark Pharmaceuticals Inc. U.S. has launched Axitinib Tablets, a generic version of Pfizer's Inlyta, in the United States for advanced kidney cancer treatment. This strategic move allows Glenmark to tap into a substantial market, with the original drug's annual sales previously reaching approximately ₹4,490 crore (USD 538.4 million) in the US.

12h ago·1 min readListen
From Chartered Accountant to Fitness Guru: Dinaz Vervatwala's Wellness Journey
real-estate

From Chartered Accountant to Fitness Guru: Dinaz Vervatwala's Wellness Journey

Dinaz Vervatwala, founder of Hyderabad's Dinaz's Fitness, transitioned from a chartered accountant to a prominent fitness and wellness coach. Her journey emphasizes holistic wellness, integrating mental health and sustainable practices, inspired by overcoming a personal accident.

3d ago·2 min readListen
Zydus Lifesciences Finalises 50% Joint Venture with Sunshine Healthcare Lanka
real-estate

Zydus Lifesciences Finalises 50% Joint Venture with Sunshine Healthcare Lanka

Zydus Lifesciences Ltd. has completed its 50:50 joint venture transaction with Sunshine Healthcare Lanka Limited, securing a 50% interest in Zydus Sunshine Lifesciences Pvt Ltd. The partnership was finalised on November 11, 2026, following an extension from its original June 2026 closing date. This strategic move aims to expand Zydus's presence through collaboration.

4d ago·1 min readListen
CCI Clears Advent International's ₹3,150 Crore Investment in Yatharth Hospitals
real-estate

CCI Clears Advent International's ₹3,150 Crore Investment in Yatharth Hospitals

The Competition Commission of India (CCI) has approved Advent International's substantial ₹3,150 crore investment in Yatharth Hospitals through its affiliate, Rasmalai Limited. This deal will grant Advent a 24.9% minority stake in the healthcare provider. Yatharth Hospitals plans to utilize these funds for its expansion efforts and to enhance its healthcare network, buoyed by strong operational revenues and profit growth.

5d ago·1 min readListen